MRVI Stock Forecast: Maravai Lifesciences Holdings, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$6.98
−2.92% on the day

The 9 Wall Street analysts covering Maravai Lifesciences Holdings, Inc. hold a median 12-month price target of $9.5 — +36.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 94 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.9B
Ticker Nerd rank
94/ 100
Median analyst target
$9.50
Analysts covering
9
Revenue$51.4M+8.5% y/y
Operating income−$15.1M
Net income−$21.6M
Free cash flow$3.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.4%
1M
−3.1%
YTD
+114.8%
1Y
+104.1%
From 52W high
−22.4%
From 52W low
+146.6%
$2.83
$9.00
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Maravai Lifesciences Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
94/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
94
Momentum
94
Accruals
91
Growth
86
Issuance
82
Value
49
Quality
41
Volatility
32

Revisions (94): Analysts have, on balance, been raising their forecasts.

Volatility (32): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MRVI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MRVI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26MRVIHigh $12.00Median $9.50Low $8.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
6
Buy
3
Hold
0
Sell
$8.00
Low
$9.50
Median
$12.00
High

The green dot is the last close — the median target sits +36.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
12 Nov 2026KeybancUpgradeOverweight$11
9 Sept 2026UBSMaintainsNeutral$2.50 → $8.00
7 Aug 2026Wells FargoMaintainsOverweight$5.50 → $6.50
8 May 2026Wells FargoMaintainsOverweight$4.50 → $5.50
15 Dec 2025Wells FargoMaintainsOverweight—
12 Aug 2025Craig-HallumMaintainsBuy—
12 Aug 2025RBC CapitalMaintainsOutperform—
13 May 2025BairdMaintainsNeutral—
13 May 2025Craig-HallumMaintainsBuy—
25 Mar 2025Morgan StanleyMaintainsEqual-Weight—
21 Mar 2025UBSMaintainsNeutral—
3 Mar 2025B of A SecuritiesMaintainsBuy—
26 Feb 2025BairdDowngradeNeutral—
5 Dec 2024Goldman SachsDowngradeSell—
14 Nov 2024Wolfe ResearchInitiatesPeer Perform—
8 Nov 2024BairdMaintainsOutperform—
8 Nov 2024RBC CapitalMaintainsOutperform—
8 Nov 2024William BlairDowngradeMarket Perform—
8 Oct 2024Goldman SachsMaintainsNeutral—
27 Aug 2024Wells FargoInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MRVI.

Market Radar

This page is one stock. Monday covers all of them.

MRVI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MRVI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Maravai Lifesciences Holdings, Inc. returned +104.1% against +6.9% for the S&P 500, dividends included.

MRVI vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26MRVIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MRVI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
8.6×

Cheaper than 13% of US stocks

Price / book
5.3×

Cheaper than 17% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
10.1%

Higher than 54% of US stocks

Earnings growth (YoY)
—
Gross margin
40.1%

Higher than 49% of US stocks

Operating margin
−24.2%

Higher than 22% of US stocks

Net margin
—
Returns & dividend
Return on equity
−29.8%

Higher than 28% of US stocks

Return on assets
−4.4%

Higher than 33% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Maravai Lifesciences Holdings, Inc. has a market value of $1.9B and an enterprise value of $1.4B.

  • Revenue in the twelve months to 30 June 2026: $208.8M. The latest quarter grew 8.5% year on year.

  • Net income over the same four quarters: −$136.1M, a −65.2% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.52.

  • Free cash flow in the twelve months to 30 June 2026: −$35.8M.

  • Shares outstanding: 148.9M.

  • Maravai Lifesciences Holdings, Inc. employs 410 people — $509K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

MRVI and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MRVIMaravai Lifesciences Holdings, Inc.$1.9B94
BHVNBiohaven Ltd.$1.8B53
REPLReplimune Group, Inc.$1.8B63
COAGHemab Therapeutics Holdings, Inc.$1.8B2
SEPNSepterna, Inc.$1.8B54
VERAVera Therapeutics, Inc.$1.8B37
IMNMImmunome, Inc.$1.9B21

Take a look at MRVI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Maravai Lifesciences Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about MRVI

What is the MRVI stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Maravai Lifesciences Holdings, Inc. have a median 12-month price target of $9.5, with estimates ranging from $8 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MRVI stock a buy right now?

Of the 9 analysts covering Maravai Lifesciences Holdings, Inc., 6 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Maravai Lifesciences Holdings, Inc. 94 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MRVI?

As at 21 Nov 2026, Maravai Lifesciences Holdings, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (94 of 100).

Will MRVI stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +36.1% from the last close, and Ticker Nerd's factor model ranks Maravai Lifesciences Holdings, Inc. 94 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MRVI stock forecast for 2030?

No analyst covering Maravai Lifesciences Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MRVI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $12 over the next 12 months.

How has MRVI stock performed over the past year?

Maravai Lifesciences Holdings, Inc. returned +104.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Maravai Lifesciences Holdings, Inc. do?

Maravai LifeSciences Holdings, Inc. Class A Common Stock represents ownership in Maravai LifeSciences Holdings, Inc., a life sciences company focused on products and services that support drug development, vaccine creation, cell and gene therapy research, and diagnostics. The company serves biopharmaceutical, biotechnology, and research customers through specialized offerings in nucleic acid production and biologics safety testing.

Company

About Maravai Lifesciences Holdings, Inc.

Maravai LifeSciences Holdings, Inc. Class A Common Stock represents ownership in Maravai LifeSciences Holdings, Inc., a life sciences company focused on products and services that support drug development, vaccine creation, cell and gene therapy research, and diagnostics. The company serves biopharmaceutical, biotechnology, and research customers through specialized offerings in nucleic acid production and biologics safety testing. Its product portfolio includes reagents, enzymes, nucleic acid tools, and analytical services used across molecular biology, genomics, and bioprocessing workflows. Maravai LifeSciences plays a role in the broader healthcare and life sciences market by supplying critical inputs that help enable laboratory research, therapeutic development, and quality testing across the drug development process. The company is headquartered in San Diego, California, and its business is organized around current operating segments that address research and production needs in advanced biologics and diagnostics.

CEO Mr. Bernd Brust · 410 employees · United States · https://www.maravai.com